Advancing the pace of innovative research is a priority for ALSF. We take risks to fund proposals embracing innovation that have been deemed highly important but have not received National Institutes of Health funding, resulting in high impact. Funding encourages established investigators to push their research forward toward childhood cancer breakthroughs and ultimately new clinical interventions.
Bio-Therapeutics Impact Grants
The Bio-Therapeutics Impact Award accelerates the development of clinical trials for promising biologic approaches to treating childhood cancer. These approaches include, but are not limited to, immunotherapy, gene therapy and small molecules. The award, intended for investigators who are initiating clinical trials or undertaking the pre-clinical work necessary to move into the IND (investigational new drug) phase, totals the maximum of $1.5 million awarded over three years.
The Bridge Grants present a funding opportunity for researchers whose projects are in jeopardy due to the decreased funding available from the National Institutes of Health (NIH). This grant is intended to keep investigations on track while reapplying for NIH funding to ensure novel childhood cancer research projects are not compromised. Awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.
Center of Excellence Grants
The Centers of Excellence (COE) program will fund selected leading childhood cancer institutions with programs committed to developing and conducting early phase clinical trials for childhood cancer and with a pediatric oncology clinical pharmacology/developmental therapeutics program. The ultimate goal of this program is to expedite the development of novel therapeutic approaches for pediatric malignancies by establishing more robust Centers of Excellence in pediatric cancer drug development and through training the next generation of leaders in preclinical and clinical drug development. COE grants are $350,000 per year, renewable annually for up to 5 years. Fifty percent of the funds must be used to enhance the Center’s clinical trial infrastructure. The remaining fifty percent must be used to support the training of physician scholars in drug development. An invitation to apply will be contingent upon receipt and review of a nomination form.
These grants are designed to support the research of investigators who have a specific focus on the epidemiology of childhood cancer, early detection of childhood cancer, or the prevention of childhood cancer. Awards are $100,000 per year for two years.
These grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. A Letter of Intent is required. The Innovation Award amount totals $250,000 over two years. The Award may not be renewed however no cost extensions are allowable.
Phase I/II Infrastructure Grants
Doctors have identified a critical lack of funding for support personnel who speed up the process of enrolling children with cancer in clinical trials. With grants from Alex's Lemonade Stand Foundation, hospitals across the country have created new positions, specifically focused on filling this critical need, bringing the latest treatments to more children.
This award is designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic keeping broader clinical testing and implementation in view. Maximum of $250,000 in total costs will be awarded over two years.
ALSF’s offers the Springboard Grant in response to cut-backs in National Institutes of Health (NIH) funding of new R01 and P01 applications. The Springboard Grant is designed to jump-start new projects with high impact potential for childhood cancer research while other funding is sought. Awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.